newest glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our Flavor:The Summer Body Set Dual GLP-1/GIP receptor agonists Prime Labs

newest glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our Flavor:The Summer Body Set Dual GLP-1/GIP receptor agonists Prime Labs

Dual GLP-1/GIP receptor agonists mechanism of action - Celtarys

Claims for GLP-1s Increased Four-Fold Between 2019 and 2024 In accordance with an increase in both the number of Medicare Part D enrollees using GLP-1s and spending on these products, the number of claims for GLP-1s increased four-fold between 2019 and 2024, from 4.8 million to 21.8 million, with claims doubling between 2022 and 2024 alone

Prime Labs

Flavor:The Summer Body Set

4 Challenges and future directions 4.1 Safety considerations The safety profile of dual or triple receptor agonists targeting GLP-1, GIP, and GCG receptors in the treatment of MASLD and related metabolic disorders warrants careful evaluation